Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
ARRY-334543, EGFR/ErbB2 inhibitor; oral
Locations
5
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Center
Nashville, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
British Columbia Cancer Agency- Centre for the Southern Interior
Kelowna, British Columbia, Canada
British Columbia Cancer Agency
Vancouver, British Columbia, Canada
Start Date
January 1, 2006
Primary Completion Date
June 1, 2009
Completion Date
June 1, 2009
Last Updated
October 14, 2020
NCT05735080
NCT04657068
NCT04900818
NCT05004116
NCT07009886
NCT06440005
Lead Sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions